Skip to main content
Premium Trial:

Request an Annual Quote

Quotient Limited Nabs CE Mark for Immunohematology Microarray

NEW YORK – Quotient Limited announced on Tuesday that it has received CE marking for its MosaiQ Extended Immunohematology Microarray. 

The approval of the microarray "substantially increases" the range of tests that can be run on the firm's MosaiQ microarray platform, Quotient said in a statement. The new solution offers antibody screening and antigen typing, including ABO forward and reverse grouping, allowing for "comprehensive characterization of blood donor sample (blood typing and disease screening) through a single test procedure," Quotient added.

"By enhancing the laboratory's ability to provide rapid, more comprehensive red blood cell phenotyping, healthcare providers can deliver better matched blood and reduce the risk of transfusion adverse events that may be life-threatening," Christine Ginocchio, Quotient's chief scientific and medical officer, said in a statement. 

MosaiQ is currently being used for blood grouping and transfusion-transmitted infection screening of donated blood and can perform multiplexing testing for immunohematology, serology, and molecular biomarkers on one platform. Quotient received CE marking for its first immunohematology microarray on MosaiQ in May 2019 and for its initial serological disease screening microarray in February 2020.